Expert Reviews: 5 Ways Trump’s FDA May Skip Drug Trials
Under Trump, the FDA is seeking to abandon traditional expert reviews for new drugs. Find out how this major policy shift could impact public health and safety.
pharmaceutical industry
Read More
New Drugs: 1 Major FDA Change Under Trump to Watch
Under Trump, the FDA seeks to abandon expert reviews of new drugs. Learn how this major policy shift could affect the safety and approval process for all new drugs.
UK drugs sector hit by Merck’s scrapped £1bn expansion
A major blow for the uk drugs sector as pharmaceutical giant Merck cancels its planned £1bn research and manufacturing hub expansion in London, citing uncertainty.
UK Investment: 5 Takeaways from the ABPI Report
A new ABPI report highlights a worrying lag in UK investment for life sciences, calling for urgent policy changes to secure the nation’s economic future.
9,000 jobs cut: Ozempic-maker Novo Nordisk restructures
Pharmaceutical giant and Ozempic-maker Novo Nordisk has announced it will cut 9,000 jobs as part of a major global restructuring plan. Find out more here.
CEO Post: Pfizer Vet Leads 1 New Phase 3 Biotech Firm
A former Pfizer executive takes the coveted ceo post at a newly formed biotech company, ready to enter Phase 3 trials. Learn more about this strategic leadership move.
Pfizer vet to lead 1 new phase 3-ready biotech as CEO
A long-time Pfizer vet has been appointed CEO of a newly formed biotech company. The firm is already poised to enter phase 3 trials for its lead candidate.
New R&D Chief: 1 Key Appointment for Merck KGaA’s Future
Merck KGaA, Darmstadt, Germany, has appointed a new R&D chief. This major executive move aims to steer the company’s future innovation and drug development pipeline.